The aRTegenTM MLL-AF4 quantitative qPCR kit is intended for quantitation of MLL-AF4 (t(4;11) (q21;q23)) fusion gene transcripts in peripheral blood or bone marrow samples.
Cat No: 556875
Key Features
- Detect and quantify MLL-AF4 (t(4;11) (q21;q23)) fusion gene transcripts.
- FAM and VIC/HEX probe-based detection system
- Capable of detecting less than 100 copies of MLL-AF4 and ABL transcripts
- Separate optimization of Reverse transcription and qPCR steps and ability to generate cDNA stock for further use.
- Two step qPCR reaction enable the test to be highly sensitive work well with limited sample amount.
Mixed Lineage Leukemia (MLL) gene arrangements are most frequent genetic alterations among human leukemia. Among them, MLL–AF4 acute lymphocytic leukemia (ALL) results from a balanced translocation between MLL and AF4 (t(4;11)(q21;q23)) with the frequency of 5–6% in infant, child and adult ALL cases and it has a poor prognosis. Detection and quantification of MLL-AF4 fusion transcripts in pediatric ALL is crucial for determination of prognosis and therapeutic approaches. The aRTegenTM MLL-AF4 quantitative qPCR kit can be used for detection and quantification of MLL‐AF4 fusion transcripts for monitoring transcript levels.
The aRTegenTM MLL-AF4 quantitative qPCR kit is for Research Use Only and not for diagnostic use.
